Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

Core Insights - Belite Bio Inc is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs [1][3] - The company will present at the dbVIC - Deutsche Bank American Depositary Receipt Virtual Investor Conference on November 4th, 2025 [1][2] - Belite's lead candidate, Tinlarebant, is currently in multiple clinical trials targeting conditions such as STGD1 and GA [3] Company Overview - Belite Bio specializes in developing therapies for degenerative retinal diseases, including STGD1 and GA in advanced dry AMD, as well as specific metabolic diseases [3] - The lead candidate, Tinlarebant, is an oral therapy aimed at reducing bisretinoid toxin accumulation in the eye and is being evaluated in Phase 3 and Phase 2/3 studies [3] Event Details - The virtual conference will allow real-time interaction between investors and the company, with an archived webcast available for those unable to attend live [2] - Participation in the event is free of charge, and pre-registration is recommended for a smoother experience [2]